{"id":"methylphenidate-mph","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Insomnia"},{"rate":"10-25","effect":"Decreased appetite"},{"rate":"5-15","effect":"Headache"},{"rate":"5-15","effect":"Nervousness or anxiety"},{"rate":"5-10","effect":"Tachycardia"},{"rate":"5-10","effect":"Abdominal pain"},{"rate":"5-10","effect":"Weight loss"}]},"_chembl":{"chemblId":"CHEMBL796","moleculeType":"Small molecule","molecularWeight":"233.31"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methylphenidate is a sympathomimetic amine that inhibits the reuptake transporters (DAT and NET) for dopamine and norepinephrine, leading to increased concentrations of these neurotransmitters in the synaptic cleft. This enhanced dopaminergic and noradrenergic signaling improves attention, focus, and impulse control in patients with attention deficit hyperactivity disorder and narcolepsy.","oneSentence":"Methylphenidate blocks the reuptake of dopamine and norepinephrine in the central nervous system, increasing their availability in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:46.983Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD)"},{"name":"Narcolepsy"}]},"trialDetails":[{"nctId":"NCT05630781","phase":"NA","title":"Orexin s Role in the Neurobiology of Substance Use Disorder","status":"RECRUITING","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2023-02-15","conditions":"Nicotine Dependence","enrollment":140},{"nctId":"NCT00768820","phase":"PHASE4","title":"The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome","status":"RECRUITING","sponsor":"The Chaim Sheba Medical Center","startDate":"2001-05","conditions":"Velocardiofacial Syndrome, Williams Syndrome, Fragile X Syndrome","enrollment":400},{"nctId":"NCT05842330","phase":"PHASE3","title":"Benefits of ADHD Treatment in Detained People","status":"RECRUITING","sponsor":"Stéphanie Baggio","startDate":"2024-01-01","conditions":"ADHD","enrollment":150},{"nctId":"NCT07226219","phase":"PHASE1","title":"Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2025-11-25","conditions":"Sickle Cell Disease, Executive Dysfunction, Cognitive Impairment","enrollment":72},{"nctId":"NCT07314333","phase":"PHASE1","title":"A Trial to Assess How Centanafadine Interacts With Stimulants in the Body","status":"RECRUITING","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2026-02-05","conditions":"ADHD","enrollment":42},{"nctId":"NCT07443800","phase":"NA","title":"Comorbidity Between Attention Deficit Hyperactivity Disorder and Fibromyalgia","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Tours","startDate":"2026-04-01","conditions":"Attention Deficit Disorder With or Without Hyperactivity","enrollment":100},{"nctId":"NCT07041333","phase":"","title":"The Effect Of Methylphenıdate Treatment On Neuroınflammatıon Levels In Chıldren Wıth Attentıon Defıcıt Hyperactıvıty Dısorder","status":"COMPLETED","sponsor":"Enes Faruk ALTUNKILIÇ","startDate":"2025-07-14","conditions":"Attention Deficit Disorder With Hyperactivity (ADHD)","enrollment":57},{"nctId":"NCT01410942","phase":"PHASE2","title":"Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-02-08","conditions":"Prostate Cancer","enrollment":175},{"nctId":"NCT06906328","phase":"NA","title":"MEthylphenidate in ADHD - Addiction(s) Comorbidity: Value of Adding a Cognitive Remediation Program to Improve Short- and Medium-term Therapeutic Response","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2025-12-11","conditions":"ADHD-add","enrollment":248},{"nctId":"NCT07301632","phase":"PHASE2","title":"Ecstasy to Alleviate SEvere Chronic Neuropathic Pain Trial","status":"RECRUITING","sponsor":"Unity Health Toronto","startDate":"2026-01-30","conditions":"Chronic Neuropathic Pain","enrollment":40},{"nctId":"NCT03511118","phase":"","title":"Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants","status":"RECRUITING","sponsor":"Duke University","startDate":"2018-10-04","conditions":"Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI","enrollment":1600},{"nctId":"NCT06063200","phase":"EARLY_PHASE1","title":"Methylphenidate and Response to Alcohol Cues Pilot Study","status":"COMPLETED","sponsor":"University of Florida","startDate":"2024-03-20","conditions":"Alcohol Use Disorder, Attention Deficit Hyperactivity Disorder","enrollment":31},{"nctId":"NCT01628029","phase":"PHASE2","title":"Cognitive Behavioral Therapy and Multimodal Therapy in Treating Sleep Disturbance in Patients With Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-01-15","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Sleep Disorder","enrollment":68},{"nctId":"NCT03652740","phase":"PHASE1","title":"Effects of Commonly Used Medications on Mood and Choice","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2018-10-02","conditions":"Healthy","enrollment":25},{"nctId":"NCT03190954","phase":"EARLY_PHASE1","title":"Brain Dopaminergic Signaling in Opioid Use Disorders","status":"COMPLETED","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"2017-08-17","conditions":"Normal Physiology, Opioid Use Disorders","enrollment":153},{"nctId":"NCT07306078","phase":"PHASE2","title":"Methylphenidate and Response to Alcohol Cues","status":"NOT_YET_RECRUITING","sponsor":"University of Florida","startDate":"2026-05","conditions":"Alcohol Use Disorder","enrollment":50},{"nctId":"NCT07333339","phase":"","title":"A Brain-Computer Interface-Based Attention Training Program Compared With Methylphenidate and Citicoline","status":"COMPLETED","sponsor":"Uludag University","startDate":"2025-02-01","conditions":"Attention Deficit Hyperactivity Disorder (ADHD), Brain Computer Interface","enrollment":174},{"nctId":"NCT02879136","phase":"EARLY_PHASE1","title":"TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease","status":"COMPLETED","sponsor":"Hubert Fernandez","startDate":"2017-01-03","conditions":"Parkinson's Disease, Idiopathic","enrollment":23},{"nctId":"NCT05776056","phase":"PHASE4","title":"Methylphenidate for the Treatment of PTSD With Associated Neurocognitive Complaints","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2024-02-05","conditions":"Posttraumatic Stress Disorder (PTSD)","enrollment":70},{"nctId":"NCT07300956","phase":"PHASE4","title":"Treating Young Children With Attention Deficit Hyperactivity Disorder","status":"NOT_YET_RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2026-02","conditions":"Attention-Deficit/Hyperactivity Disorder (ADHD)","enrollment":370},{"nctId":"NCT06977308","phase":"PHASE1","title":"A Multimodal Imaging Study of Dopamine in Early Psychosis","status":"NOT_YET_RECRUITING","sponsor":"New York State Psychiatric Institute","startDate":"2026-03-01","conditions":"Clinical High Risk for Psychosis (CHR)","enrollment":115},{"nctId":"NCT05301361","phase":"PHASE1","title":"Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities","status":"ENROLLING_BY_INVITATION","sponsor":"University of California, Davis","startDate":"2023-02-01","conditions":"Intellectual Disability, Fragile X Syndrome, Down Syndrome","enrollment":68},{"nctId":"NCT05414058","phase":"PHASE2","title":"Adjunctive Methylphenidate ER in Patients With Schizophrenia to Improve Functional and Cognitive Outcomes","status":"COMPLETED","sponsor":"The Royal Ottawa Mental Health Centre","startDate":"2022-09-09","conditions":"Schizophrenia Schizoaffective","enrollment":35},{"nctId":"NCT07279740","phase":"PHASE2","title":"Combined Brain Stimulation and Methylphenidate Treatment for Apathy in Dementia","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2026-01","conditions":"Alzheimer s Disease, Alzheimer Dementia (AD), Alzheimer Dementia","enrollment":12},{"nctId":"NCT06905587","phase":"PHASE3","title":"Methylphenidate in Pediatric Brain Tumor Survivors With Cancer-related Fatigue","status":"RECRUITING","sponsor":"Odense University Hospital","startDate":"2025-09-02","conditions":"Brain Tumor, Pediatric, Cancer-related Fatigue, Methylphenidate","enrollment":50},{"nctId":"NCT03280251","phase":"PHASE2","title":"Methylphenidate and Cognitive Training in Elderly","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2018-09-19","conditions":"Healthy Volunteers","enrollment":31},{"nctId":"NCT07273695","phase":"","title":"Assessing Real Life Effectiveness of Treatment in Neurodevelopmental Disorders","status":"RECRUITING","sponsor":"IRCCS Eugenio Medea","startDate":"2025-09-19","conditions":"Emotional Dysregulation, Externalizing Problems, Oppositional Defiant","enrollment":80},{"nctId":"NCT06221358","phase":"","title":"Pharmacogenomics of Stimulant Treatment Response","status":"RECRUITING","sponsor":"University of Calgary","startDate":"2024-04-01","conditions":"Attention-Deficit/ Hyperactivity Disorder (ADHD)","enrollment":400},{"nctId":"NCT06081179","phase":"PHASE1","title":"Does Serotonin System Stimulation Increase Pro-social Behavior? - A Comparative Pharmacological Neuroscientific Study in Healthy Humans","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2023-10-24","conditions":"Healthy","enrollment":122},{"nctId":"NCT05185583","phase":"PHASE2","title":"Methylphenidate in Childhood Apraxia of Speech","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2022-03-14","conditions":"Childhood Apraxia of Speech","enrollment":18},{"nctId":"NCT05474846","phase":"PHASE2, PHASE3","title":"Combination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-11-21","conditions":"Sleep, Fatigue, Anxiety","enrollment":188},{"nctId":"NCT06431256","phase":"PHASE3","title":"Efficacy, Safety & Pharmacokinetic (PK) Study of HLD200 in Children Aged 4-5 Years With ADHD","status":"TERMINATED","sponsor":"Ironshore Pharmaceuticals and Development, Inc","startDate":"2024-09-13","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":26},{"nctId":"NCT04501653","phase":"EARLY_PHASE1","title":"Precision Functional Brain Mapping in Psilocybin","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2021-06-01","conditions":"Psilocybin","enrollment":11},{"nctId":"NCT03814356","phase":"PHASE1","title":"Stimulant Therapy Targeted to Individualized Connectivity Maps to Promote ReACTivation of Consciousness","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-08-24","conditions":"Brain Injury Traumatic Severe (Diagnosis), Coma, Consciousness, Level Altered","enrollment":10},{"nctId":"NCT05916339","phase":"PHASE4","title":"AWARE: Management of ADHD in Autism Spectrum Disorder","status":"RECRUITING","sponsor":"Daniel Coury","startDate":"2023-10-01","conditions":"ADHD, Autism Spectrum Disorder","enrollment":500},{"nctId":"NCT05761756","phase":"NA","title":"Oxygen Toxicity: Mechanisms in Humans","status":"RECRUITING","sponsor":"Duke University","startDate":"2023-11-28","conditions":"Oxygen Toxicity, Hypercapnia, Seizures","enrollment":62},{"nctId":"NCT03525873","phase":"PHASE3","title":"A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-08-02","conditions":"Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm","enrollment":212},{"nctId":"NCT04781972","phase":"PHASE4","title":"Multimodal Brain Imaging of the Neural Effects of Methylphenidate in Patients With ADHD","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2021-07-27","conditions":"ADHD - Combined Type","enrollment":30},{"nctId":"NCT06355414","phase":"PHASE1","title":"Psilocybin in Chronic Low Back Pain and Depression","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2024-04-22","conditions":"Chronic Low-back Pain, Depression","enrollment":40},{"nctId":"NCT03772834","phase":"PHASE2, PHASE3","title":"Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients With Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-03-25","conditions":"Prostate Carcinoma","enrollment":200},{"nctId":"NCT05978167","phase":"EARLY_PHASE1","title":"Targeting Drug Memories With Methylphenidate","status":"ACTIVE_NOT_RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2023-07-05","conditions":"Substance Use Disorder, Cocaine Use Disorder","enrollment":51},{"nctId":"NCT05721235","phase":"PHASE4","title":"A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD","status":"COMPLETED","sponsor":"Corium, Inc.","startDate":"2023-06-02","conditions":"Attention Deficit/Hyperactivity Disorder","enrollment":123},{"nctId":"NCT06580041","phase":"PHASE4","title":"Precision Care for Major Depressive Disorder","status":"ENROLLING_BY_INVITATION","sponsor":"University of California, San Francisco","startDate":"2024-11-12","conditions":"Major Depressive Disorder, Depression, Depressive Disorder, Major","enrollment":150},{"nctId":"NCT02286557","phase":"PHASE2","title":"Testing the Effects of Methylphenidate on Multiple Sclerosis","status":"COMPLETED","sponsor":"Kessler Foundation","startDate":"2014-10","conditions":"Fatigue in Multiple Sclerosis","enrollment":36},{"nctId":"NCT05469386","phase":"PHASE4","title":"Single and Combined Effects of Behavioral, Academic, and Medication Treatments for ADHD in the Classroom","status":"ACTIVE_NOT_RECRUITING","sponsor":"Florida International University","startDate":"2022-06-13","conditions":"ADHD","enrollment":288},{"nctId":"NCT05924594","phase":"PHASE3","title":"Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301","status":"SUSPENDED","sponsor":"Cingulate Therapeutics","startDate":"2023-07-31","conditions":"ADHD, ADHD - Combined Type, Attention Deficit Hyper Activity","enrollment":45},{"nctId":"NCT07121621","phase":"PHASE4","title":"PHArmaCokinetics of methYLphenidate in Adult Patients With Attention-Deficit /Hyperactivity Disorder","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Tours","startDate":"2025-09-01","conditions":"Attention Deficit Hyperactivity Disorder (ADHD), Obesity (Body Mass Index &Amp;Amp;gt;30 kg/m2), Methylphenidate","enrollment":30},{"nctId":"NCT07119073","phase":"PHASE1","title":"In-clinic Crossover Study in Subjects With Two Treatments (Fed vs Fasted)","status":"COMPLETED","sponsor":"Cingulate Therapeutics","startDate":"2024-10-31","conditions":"Healthy Volunteers in Fed and Fasted State","enrollment":25},{"nctId":"NCT03511976","phase":"PHASE4","title":"Adaptive Response to Intervention (RTI) for Students With ADHD","status":"WITHDRAWN","sponsor":"Florida International University","startDate":"2018-05-14","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":""},{"nctId":"NCT05536011","phase":"","title":"WAKIX® (Pitolisant) Pregnancy Registry","status":"RECRUITING","sponsor":"Harmony Biosciences Management, Inc.","startDate":"2021-08-24","conditions":"Pregnancy Related, Narcolepsy","enrollment":1329},{"nctId":"NCT05561205","phase":"NA","title":"rTMS for Apathy Clinical Trial","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2023-02-09","conditions":"Alzheimer Disease, Apathy in Dementia, Dementia","enrollment":10},{"nctId":"NCT03440190","phase":"","title":"Bariatric Surgery and Pharmacokinetics of Methylphenidate","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2018-01-02","conditions":"Obesity, Morbid","enrollment":1},{"nctId":"NCT04132557","phase":"","title":"A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-10-09","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":430000},{"nctId":"NCT06577779","phase":"PHASE4","title":"An Open-Label Treatment With Randomization Observation, Investigator-Initiated Study, on the Duration and Efficacy of Jornay PM (Methylphenidate Hydrochloride Extended-Release Capsules) on Adult ADHD Symptoms and Executive Function and Emotional Regulation Throughout the Day Into Early Evening","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-01-29","conditions":"Attention-deficit/Hyperactivity Disorder","enrollment":30},{"nctId":"NCT04885257","phase":"PHASE1, PHASE2","title":"Methylphenidate for Ptsd and Stroke Veterans","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2022-01-14","conditions":"PTSD, Stroke","enrollment":20},{"nctId":"NCT04421248","phase":"PHASE4","title":"Biomarker Validation in Motor System Physiology in Attention Deficit Hyperactivity Disorder","status":"RECRUITING","sponsor":"Donald Gilbert, MD, MS, FAAN, FAAP","startDate":"2020-09-01","conditions":"Attention Deficit Hyperactivity Disorder Combined","enrollment":214},{"nctId":"NCT05880342","phase":"PHASE3","title":"The Role of the Brain in Mental and Physical Fatigue","status":"RECRUITING","sponsor":"Vrije Universiteit Brussel","startDate":"2023-05-03","conditions":"Fatigue","enrollment":62},{"nctId":"NCT07024303","phase":"EARLY_PHASE1","title":"Measurement of Treatment Effects","status":"NOT_YET_RECRUITING","sponsor":"Matthew J O'Brien, PhD, BCBA-D","startDate":"2025-06-15","conditions":"Challenging Behavior, Autism Spectrum Disorder","enrollment":20},{"nctId":"NCT06369714","phase":"NA","title":"Neurofeedback-Based Digital Therapeutics for the Diagnosis and Treatment of ADHD in Children.","status":"RECRUITING","sponsor":"Lei Lei, MD","startDate":"2023-02-24","conditions":"Attention Deficit Disorder With Hyperactivity, Executive Function Disorder","enrollment":210},{"nctId":"NCT06844812","phase":"","title":"The Effect of Methylphenidate Treatment on Oxidative Stress Levels in Children Diagnosed With Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Saglik Bilimleri Universitesi","startDate":"2024-06-26","conditions":"Attention Deficit Hyperactivity Disorder (ADHD)","enrollment":39},{"nctId":"NCT05685732","phase":"PHASE4","title":"An Efficacy and Safety Study w/ Azstarys® in Children 4-12 Years of Age With ADHD","status":"COMPLETED","sponsor":"Corium, Inc.","startDate":"2023-03-22","conditions":"Attention Deficit/Hyperactivity Disorder","enrollment":246},{"nctId":"NCT04113551","phase":"","title":"A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-10-01","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":17418},{"nctId":"NCT03575403","phase":"PHASE1","title":"Behavioral Effects of Drugs: Inpatient (36) (Alcohol, Duloxetine, and Methylphenidate)","status":"COMPLETED","sponsor":"Craig Rush","startDate":"2018-09-01","conditions":"Alcohol Use Disorder","enrollment":19},{"nctId":"NCT04419272","phase":"PHASE4","title":"Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2023-08-14","conditions":"Epilepsy","enrollment":226},{"nctId":"NCT03190681","phase":"EARLY_PHASE1","title":"Motivation and Methylphenidate","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2017-07-11","conditions":"Motivation, Apathy, Impulsive Behavior","enrollment":35},{"nctId":"NCT05133804","phase":"PHASE2","title":"Efficacy of Reboxetine and Methylphenidate Treatment on Attentional, Sensory and Emotional Dysregulation in Adults With PTSD","status":"RECRUITING","sponsor":"University of Haifa","startDate":"2022-06-01","conditions":"Posttraumatic Stress Disorder","enrollment":53},{"nctId":"NCT03420339","phase":"PHASE4","title":"Stimulant Effects on Disruptive Behavior","status":"RECRUITING","sponsor":"Matthew J O'Brien, PhD, BCBA-D","startDate":"2018-10-01","conditions":"Attention Deficit Hyperactivity Disorder, Problem Behavior","enrollment":10},{"nctId":"NCT05066009","phase":"NA","title":"Sleep/Wake State Assessment with Non-invasive Earbuds","status":"COMPLETED","sponsor":"Emory University","startDate":"2021-10-13","conditions":"Hypersomnolence","enrollment":8},{"nctId":"NCT06797570","phase":"NA","title":"The Primary Objective of This Study is to Determine Whether Positively Framed Information (PFI) on Side Effects, Compared to Negatively Framed and Extensive Information (NFI) Can Reduce the Number and Severity of Reported Adverse Events Caused by ADHD Medication in Children Aged 7 to 17 Years.","status":"NOT_YET_RECRUITING","sponsor":"St. Antonius Hospital","startDate":"2025-01-25","conditions":"Attention Deficit Disorder, Attention Deficit Disorder (ADD), Attention Deficit Disorder with Hyperactivity","enrollment":130},{"nctId":"NCT05285683","phase":"PHASE2","title":"The Role of Brain Dopamine in Chronic Pain","status":"RECRUITING","sponsor":"University of Rochester","startDate":"2024-01-31","conditions":"Chronic Pain","enrollment":10},{"nctId":"NCT04219280","phase":"PHASE4","title":"Evaluating Treatment of ADHD in Children with Down Syndrome","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2020-10-02","conditions":"Down Syndrome, ADHD","enrollment":100},{"nctId":"NCT06759298","phase":"EARLY_PHASE1","title":"The Effects of Methylphenidate on Symptomatology in Individuals With Borderline Personality Disorder","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2025-01-15","conditions":"Borderline Personality Disorder","enrollment":60},{"nctId":"NCT06465641","phase":"PHASE4","title":"Methylphenidate in KBG Syndrome: N-of-1 Series","status":"RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2024-11-13","conditions":"Kbg Syndrome, ADHD - Combined Type","enrollment":15},{"nctId":"NCT05650775","phase":"PHASE1","title":"Biomarkers of ADHD Treatment Response","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2023-02-17","conditions":"ADHD","enrollment":16},{"nctId":"NCT06232226","phase":"NA","title":"Attention Deficit Hyperactivity Disorder","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-04-11","conditions":"Attention Deficit Hyperactivity Disorder, Behavior Hyperactive, Behavior Disorders","enrollment":60},{"nctId":"NCT05957055","phase":"PHASE2","title":"Lisdexamphetamine Vs Methylphenidate for Pediatric Patients with ADHD and Type 1 Diabetes","status":"RECRUITING","sponsor":"Medical University of Lodz","startDate":"2024-02-05","conditions":"Attention Deficit Disorder with Hyperactivity, Diabetes Mellitus, Type 1","enrollment":150},{"nctId":"NCT04737512","phase":"EARLY_PHASE1","title":"Mindfulness-Based ADHD Treatment for Children: a Feasibility Study","status":"COMPLETED","sponsor":"Yale University","startDate":"2021-02-01","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":68},{"nctId":"NCT02855229","phase":"","title":"Novel Cross-Species Neurophysiological Assays of Reward and Cognitive Domains","status":"COMPLETED","sponsor":"Mclean Hospital","startDate":"2020-08-15","conditions":"Translational Electrophysiology","enrollment":222},{"nctId":"NCT00792662","phase":"PHASE4","title":"Improving Function, Quality of Life, Glycemia in Diabetics With Dementia","status":"WITHDRAWN","sponsor":"University of Nebraska","startDate":"2008-11-18","conditions":"Diabetes Mellitus, Alzheimer's Disease, Apathy","enrollment":""},{"nctId":"NCT00580814","phase":"NA","title":"Brain Dopamine Function in Adults With ADHD","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2006-02","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":75},{"nctId":"NCT00829673","phase":"PHASE1","title":"Dexmethylphenidate Hydrochloride Tablets Under Non-Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2004-06","conditions":"Healthy","enrollment":24},{"nctId":"NCT00829712","phase":"PHASE1","title":"Dexmethylphenidate Hydrochloride Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2004-06","conditions":"Healthy","enrollment":24},{"nctId":"NCT01351272","phase":"PHASE3","title":"Genetic Modulation of Working Memory in Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Wuerzburg University Hospital","startDate":"2011-05","conditions":"ADHD","enrollment":41},{"nctId":"NCT03781752","phase":"PHASE4","title":"Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2018-03-04","conditions":"ADHD, Attention Deficit Hyperactivity Disorder","enrollment":500},{"nctId":"NCT03781765","phase":"PHASE4","title":"Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2019-06-04","conditions":"ADHD, Attention Deficit Hyperactivity Disorder","enrollment":44},{"nctId":"NCT05832489","phase":"PHASE3","title":"EEG-MRI Imaging of Methylphenidate Effects in Adult ADHD and Attentional Symptoms in Mood Disorders","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2024-02-26","conditions":"Adult ADHD, Adult-onset ADHD With Mood Disorder","enrollment":80},{"nctId":"NCT06518330","phase":"","title":"Psychosis Associated With Methylphenidate in Children and Adolescents","status":"COMPLETED","sponsor":"University Hospital, Caen","startDate":"1967-01-01","conditions":"Psychosis","enrollment":46233},{"nctId":"NCT04603391","phase":"PHASE4","title":"Cannabidiol and CES1 Interactions in Healthy Subjects","status":"COMPLETED","sponsor":"University of Florida","startDate":"2021-02-25","conditions":"Drug Interaction","enrollment":14},{"nctId":"NCT04823364","phase":"NA","title":"Evaluation of Brain Neurotransmitter Levels in Adults With ADHD, Before and After Stimulant Treatment","status":"TERMINATED","sponsor":"Weizmann Institute of Science","startDate":"2024-07-11","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":60},{"nctId":"NCT02096952","phase":"PHASE4","title":"Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2014-05","conditions":"Attention-deficit/Hyperactivity Disorder, Autism Spectrum Disorder","enrollment":15},{"nctId":"NCT03326245","phase":"PHASE1","title":"Dopaminergic Modulation of Brain Activation Using Simultaneous PET/Pharmacological MRI","status":"COMPLETED","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"2018-01-29","conditions":"Normal Physiology","enrollment":25},{"nctId":"NCT04273880","phase":"PHASE1","title":"Differences by Sex and Genotype in the Effects of Stress on Executive Functions","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2018-04-28","conditions":"Stress","enrollment":146},{"nctId":"NCT02167048","phase":"PHASE1, PHASE2","title":"Low-dose vs. Normal-dose Psychostimulants on Executive Functions in Individuals With ADHD","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of British Columbia","startDate":"2014-06","conditions":"Attention Deficit Hyperactivity Disorders","enrollment":52},{"nctId":"NCT04384562","phase":"NA","title":"Studying the Role of Brain Molecules for Decision Making","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2020-12-17","conditions":"Decision Making, Healthy","enrollment":160},{"nctId":"NCT05669924","phase":"PHASE2","title":"Neural Correlates of Acute Pain Dynamics","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2022-09-19","conditions":"Pain","enrollment":40},{"nctId":"NCT02233829","phase":"EARLY_PHASE1","title":"Dopamine Rhythms in Health and Addiction","status":"WITHDRAWN","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"2024-04-23","conditions":"Cocaine Abuse","enrollment":""},{"nctId":"NCT03936491","phase":"NA","title":"The Neuroprotective Effects of Methylphenidate and Atomoxetine in Children With ADHD: A Lipidomic Study","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2019-08-01","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":105},{"nctId":"NCT06073470","phase":"","title":"Metabolic Mechanisms of the Electrophysiological Biomarkers for Response to Methylphenidate Treatment in Children With ADHD","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2024-01-01","conditions":"Methylphenidate, Metabolomics","enrollment":160},{"nctId":"NCT06077669","phase":"PHASE4","title":"Multimodal Brain Imaging of Methylphenidate in Children and Adolescents With ADHD","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2024-04-16","conditions":"ADHD","enrollment":""},{"nctId":"NCT05522478","phase":"","title":"Effect Of Methylphenidate On Balance In Children With Attention Deficit Hyperactivity Disorder","status":"COMPLETED","sponsor":"Fatih Sultan Mehmet Training and Research Hospital","startDate":"2016-07","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":85}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1687,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Focalin XR","Methylphenidate long acting","Medikinet retard","Metadate CD®","Concerta®"],"phase":"marketed","status":"active","brandName":"Methylphenidate (MPH)","genericName":"Methylphenidate (MPH)","companyName":"University of California, Los Angeles","companyId":"university-of-california-los-angeles","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Methylphenidate blocks the reuptake of dopamine and norepinephrine in the central nervous system, increasing their availability in the brain. Used for Attention-deficit/hyperactivity disorder (ADHD), Narcolepsy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}